Metagenomi Technologies, LLC Files S-1 Registration Statement

Ticker: MGX · Form: S-1 · Filed: Jan 5, 2024 · CIK: 1785279

Metagenomi Technologies, LLC S-1 Filing Summary
FieldDetail
CompanyMetagenomi Technologies, LLC (MGX)
Form TypeS-1
Filed DateJan 5, 2024
Risk Levellow
Pages15
Reading Time18 min
Sentimentneutral

Complexity: moderate

Sentiment: neutral

Topics: S-1 Filing, IPO, Metagenomi Technologies, Registration Statement, Emerging Growth Company

TL;DR

<b>Metagenomi Technologies, LLC has filed an S-1 registration statement for its initial public offering.</b>

AI Summary

Metagenomi Technologies, LLC (MGX) filed a IPO Registration (S-1) with the SEC on January 5, 2024. Metagenomi Technologies, LLC, to be succeeded by Metagenomi, Inc., has filed an S-1 registration statement. The company is incorporated in Delaware and its fiscal year ends on December 31. Its principal executive offices are located at 1545 Park Avenue, Emeryville, California. The filing is made under the Securities Act of 1933. Metagenomi Technologies, LLC is classified as a non-accelerated filer and an emerging growth company.

Why It Matters

For investors and stakeholders tracking Metagenomi Technologies, LLC, this filing contains several important signals. This S-1 filing is a prerequisite for Metagenomi Technologies, LLC to become a publicly traded company, allowing it to raise capital from public investors. The filing provides detailed information about the company's business, financial condition, and management, which is crucial for potential investors to make informed decisions.

Risk Assessment

Risk Level: low — Metagenomi Technologies, LLC shows low risk based on this filing. The filing is an S-1, which is a preliminary step for an IPO and does not contain operational or financial performance data yet, indicating a low immediate risk based solely on this document.

Analyst Insight

Monitor future filings for detailed financial performance, business strategy, and market reception following the potential IPO.

Key Numbers

  • 2836 — Standard Industrial Classification Code (BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES))
  • 832735153 — IRS Employer Identification No.
  • 333-276413 — SEC File Number
  • 2024-01-05 — Filing Date

Key Players & Entities

  • Metagenomi Technologies, LLC (company) — Registrant name
  • Metagenomi, Inc. (company) — Name to be succeeded by
  • Delaware (jurisdiction) — State of incorporation
  • 1545 Park Avenue, Emeryville, California (location) — Principal executive offices address
  • Brian C. Thomas, Ph.D. (person) — Chief Executive Officer
  • Goodwin Procter LLP (company) — Legal counsel
  • Davis Polk & Wardwell LLP (company) — Legal counsel
  • Securities Act of 1933 (regulation) — Act under which registration is filed

Forward-Looking Statements

  • Metagenomi, Inc. will complete its initial public offering. (Metagenomi, Inc.) — medium confidence, target: 2024-12-31

FAQ

When did Metagenomi Technologies, LLC file this S-1?

Metagenomi Technologies, LLC filed this IPO Registration (S-1) with the SEC on January 5, 2024.

What is a S-1 filing?

A S-1 is a registration statement for initial public offerings, containing the prospectus with business description, financials, and risk factors. This particular S-1 was filed by Metagenomi Technologies, LLC (MGX).

Where can I read the original S-1 filing from Metagenomi Technologies, LLC?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Metagenomi Technologies, LLC.

What are the key takeaways from Metagenomi Technologies, LLC's S-1?

Metagenomi Technologies, LLC filed this S-1 on January 5, 2024. Key takeaways: Metagenomi Technologies, LLC, to be succeeded by Metagenomi, Inc., has filed an S-1 registration statement.. The company is incorporated in Delaware and its fiscal year ends on December 31.. Its principal executive offices are located at 1545 Park Avenue, Emeryville, California..

Is Metagenomi Technologies, LLC a risky investment based on this filing?

Based on this S-1, Metagenomi Technologies, LLC presents a relatively low-risk profile. The filing is an S-1, which is a preliminary step for an IPO and does not contain operational or financial performance data yet, indicating a low immediate risk based solely on this document.

What should investors do after reading Metagenomi Technologies, LLC's S-1?

Monitor future filings for detailed financial performance, business strategy, and market reception following the potential IPO. The overall sentiment from this filing is neutral.

How does Metagenomi Technologies, LLC compare to its industry peers?

Metagenomi Technologies operates in the biotechnology sector, focusing on developing novel solutions potentially related to biological products.

Are there regulatory concerns for Metagenomi Technologies, LLC?

The filing is made under the Securities Act of 1933, which governs the registration of securities offerings in the United States.

Industry Context

Metagenomi Technologies operates in the biotechnology sector, focusing on developing novel solutions potentially related to biological products.

Regulatory Implications

The filing is made under the Securities Act of 1933, which governs the registration of securities offerings in the United States.

What Investors Should Do

  1. Review the full S-1 filing for detailed business description and risk factors.
  2. Track subsequent SEC filings (e.g., amendments to S-1, S-4, 10-K, 10-Q) for financial and operational updates.
  3. Monitor news and analyst reports regarding Metagenomi Technologies' progress towards an IPO and its market potential.

Key Dates

  • 2024-01-05: S-1 Filing — Initial registration statement filed with the SEC, marking a step towards a potential IPO.

Year-Over-Year Comparison

This is the initial S-1 filing, so there is no prior filing data to compare against.

Filing Stats: 4,438 words · 18 min read · ~15 pages · Grade level 15.9 · Accepted 2024-01-05 17:16:47

Filing Documents

Risk Factors

Risk Factors 18 Special Note Regarding Forward-Looking Statements 90 Reorganization 92

Use of Proceeds

Use of Proceeds 94 Dividend Policy 95 Capitalization 96

Managements Discussion and Analysis of Financial Condition and Results of Operations

Managements Discussion and Analysis of Financial Condition and Results of Operations 101

Business

Business 129 Management 227

Executive Compensation

Executive Compensation 237 Director Compensation 248 Certain Relationships and Related Person Transactions 250 Principal Stockholders 254

Description of Capital Stock

Description of Capital Stock 256 Shares Eligible for Future Sale 262 Material U.S. Federal Income Tax Considerations for Non-U.S. Holders 264

Underwriting

Underwriting 268 Legal Matters 282 Experts 282 Changes in Independent Registered Public Accounting Firm 282 Where You Can Find More Information 283 Index to Consolidated Financial Statements F-1 We have not, and the underwriters have not, authorized anyone to provide any information or to make any representation other than those contained in this prospectus, any amendment or supplement to this prospectus or any free writing prospectuses prepared by or on behalf of us or to which we have referred you. We and the underwriters take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the shares of common stock offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus, any amendment or supplement to this prospectus or any applicable free writing prospectus is current only as of its date, regardless of its time of delivery or any sale of shares of our common stock. Our business, financial condition, results of operations and prospects may have changed since that date. i Table of Contents For investors outside the United States: We have not, and the underwriters have not, done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of common stock and the distribution of this prospectus outside the United States. Market data and certain other statistical information used throughout this prospectus are based on independent industry publications, governmental publications, reports by market research firms, or other independent sources that we believ

View Full Filing

View this S-1 filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.